Response to Gringeri et al.: ‘recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling’

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|6|e489-e492

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.6, 2015-11, pp. : e489-e492

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 300-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 766-771

John Wiley & Sons Inc

Access to resources Recommend Favorite

Author's response: ‘Transition considerations for extended half‐life factor products’

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : e454-e455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Author's response: ‘Transition considerations for extended half‐life factor products’

By  

HAEMOPHILIA, Vol. 21, Iss. 5, 2015-09 ,pp. : e454-e455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Half‐life extended factor VIII for the treatment of hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S176-S179

John Wiley & Sons Inc

Access to resources Recommend Favorite